[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

CL2022000264A1 - Síntesis de un inhibidor de calicreína plasmática a escala de proceso - Google Patents

Síntesis de un inhibidor de calicreína plasmática a escala de proceso

Info

Publication number
CL2022000264A1
CL2022000264A1 CL2022000264A CL2022000264A CL2022000264A1 CL 2022000264 A1 CL2022000264 A1 CL 2022000264A1 CL 2022000264 A CL2022000264 A CL 2022000264A CL 2022000264 A CL2022000264 A CL 2022000264A CL 2022000264 A1 CL2022000264 A1 CL 2022000264A1
Authority
CL
Chile
Prior art keywords
synthesis
plasma kallikrein
kallikrein inhibitor
scale plasma
scale
Prior art date
Application number
CL2022000264A
Other languages
English (en)
Inventor
Yahya El-Kattan
Yarlagadda S Babu
Original Assignee
Biocryst Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biocryst Pharm Inc filed Critical Biocryst Pharm Inc
Publication of CL2022000264A1 publication Critical patent/CL2022000264A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C253/00—Preparation of carboxylic acid nitriles
    • C07C253/30—Preparation of carboxylic acid nitriles by reactions not involving the formation of cyano groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00—Carboxylic acid nitriles
    • C07C255/49—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C255/58—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing cyano groups and singly-bound nitrogen atoms, not being further bound to other hetero atoms, bound to the carbon skeleton
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Physical Or Chemical Processes And Apparatus (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Steroid Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

Métodos para preparar el Compuesto I, y sus sales. Dichos métodos de preparación del Compuesto I son apropiados para usar a escala de proceso. I.
CL2022000264A 2019-08-06 2022-02-01 Síntesis de un inhibidor de calicreína plasmática a escala de proceso CL2022000264A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201962883396P 2019-08-06 2019-08-06

Publications (1)

Publication Number Publication Date
CL2022000264A1 true CL2022000264A1 (es) 2022-10-21

Family

ID=74504082

Family Applications (2)

Application Number Title Priority Date Filing Date
CL2022000264A CL2022000264A1 (es) 2019-08-06 2022-02-01 Síntesis de un inhibidor de calicreína plasmática a escala de proceso
CL2023000942A CL2023000942A1 (es) 2019-08-06 2023-03-30 Síntesis de un inhibidor de calicreína plasmática a escala de proceso .

Family Applications After (1)

Application Number Title Priority Date Filing Date
CL2023000942A CL2023000942A1 (es) 2019-08-06 2023-03-30 Síntesis de un inhibidor de calicreína plasmática a escala de proceso .

Country Status (20)

Country Link
US (1) US20220289683A1 (es)
EP (1) EP4010320A4 (es)
JP (1) JP2022543419A (es)
KR (1) KR20220044276A (es)
CN (1) CN114206839A (es)
AR (1) AR119617A1 (es)
AU (1) AU2020324422A1 (es)
BR (1) BR112022002060A2 (es)
CA (1) CA3149176A1 (es)
CL (2) CL2022000264A1 (es)
CO (1) CO2022002392A2 (es)
CR (1) CR20220092A (es)
EC (1) ECSP22016209A (es)
IL (1) IL290113A (es)
JO (1) JOP20220021A1 (es)
MX (1) MX2022001608A (es)
PE (1) PE20221009A1 (es)
TW (1) TW202120481A (es)
UY (1) UY38826A (es)
WO (1) WO2021026182A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS61159B1 (sr) 2014-03-07 2021-01-29 Biocryst Pharm Inc Pirazoli supstituisani trifluorometilom kao inhibitori humanog kalikreina plazme
CN116375648A (zh) * 2023-03-22 2023-07-04 苏州农平科技发展有限公司 贝罗司他中间体的制备方法

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4559157A (en) 1983-04-21 1985-12-17 Creative Products Resource Associates, Ltd. Cosmetic applicator useful for skin moisturizing
LU84979A1 (fr) 1983-08-30 1985-04-24 Oreal Composition cosmetique ou pharmaceutique sous forme aqueuse ou anhydre dont la phase grasse contient un polyether oligomere et polyethers oligomeres nouveaux
LU86084A1 (fr) 1985-09-20 1987-04-02 Faco Sa Apparei de massage electrique
US5102417A (en) 1985-11-07 1992-04-07 Expandable Grafts Partnership Expandable intraluminal graft, and method and apparatus for implanting an expandable intraluminal graft
US4800882A (en) 1987-03-13 1989-01-31 Cook Incorporated Endovascular stent and delivery system
US4820508A (en) 1987-06-23 1989-04-11 Neutrogena Corporation Skin protective composition
US4886062A (en) 1987-10-19 1989-12-12 Medtronic, Inc. Intravascular radially expandable stent and method of implant
US4992478A (en) 1988-04-04 1991-02-12 Warner-Lambert Company Antiinflammatory skin moisturizing composition and method of preparing same
US4938949A (en) 1988-09-12 1990-07-03 University Of New York Treatment of damaged bone marrow and dosage units therefor
WO1990013332A1 (en) 1989-05-11 1990-11-15 Cedars-Sinai Medical Center Stent with sustained drug delivery
EP0470246B1 (en) 1990-02-28 1995-06-28 Medtronic, Inc. Intralumenal drug eluting prosthesis
US5429634A (en) 1993-09-09 1995-07-04 Pdt Systems Biogenic implant for drug delivery and method
US5419760A (en) 1993-01-08 1995-05-30 Pdt Systems, Inc. Medicament dispensing stent for prevention of restenosis of a blood vessel
US6774278B1 (en) 1995-06-07 2004-08-10 Cook Incorporated Coated implantable medical device
EP1417200B1 (en) * 2001-08-13 2010-06-02 E.I. Du Pont De Nemours And Company Substituted 1h-dihydropyrazoles, their preparation and use
US6770729B2 (en) 2002-09-30 2004-08-03 Medtronic Minimed, Inc. Polymer compositions containing bioactive agents and methods for their use
CA2747035C (en) * 2008-12-18 2017-01-24 Bayer Cropscience Ag Tetrazole substituted anthranilic acid amides as pesticides
RS61159B1 (sr) 2014-03-07 2021-01-29 Biocryst Pharm Inc Pirazoli supstituisani trifluorometilom kao inhibitori humanog kalikreina plazme

Also Published As

Publication number Publication date
JOP20220021A1 (ar) 2023-01-30
EP4010320A4 (en) 2023-08-16
CO2022002392A2 (es) 2022-04-08
WO2021026182A1 (en) 2021-02-11
CR20220092A (es) 2022-06-03
BR112022002060A2 (pt) 2022-06-07
IL290113A (en) 2022-03-01
PE20221009A1 (es) 2022-06-15
UY38826A (es) 2021-02-26
CA3149176A1 (en) 2021-02-11
AR119617A1 (es) 2021-12-29
CL2023000942A1 (es) 2023-11-24
MX2022001608A (es) 2022-03-11
ECSP22016209A (es) 2022-06-30
TW202120481A (zh) 2021-06-01
EP4010320A1 (en) 2022-06-15
AU2020324422A1 (en) 2022-03-17
CN114206839A (zh) 2022-03-18
US20220289683A1 (en) 2022-09-15
KR20220044276A (ko) 2022-04-07
JP2022543419A (ja) 2022-10-12

Similar Documents

Publication Publication Date Title
CL2023000942A1 (es) Síntesis de un inhibidor de calicreína plasmática a escala de proceso .
CO2018009275A2 (es) Derivados pirrolidina espiro-condensados como inhibidores de enzimas desubiquitinantes (dub)
CO2019010035A2 (es) Síntesis de inhibidor de mcl-1
CO2022002637A2 (es) Proceso de fabricación de moduladores de cftr
CO2018013827A2 (es) Procesos para preparar oligómeros de morfolino fosforodiamidato
BR112019004161A2 (pt) novo promotor e uso do mesmo
CO2018013834A2 (es) Procesos para preparar oligómeros de morfolino fosforodiamidato
CO2018013838A2 (es) Procesos para preparar oligómeros
CO2020001861A2 (es) Inhibidores de ror gamma
CL2019003057A1 (es) Compuestos antitumorales.
CL2023002667A1 (es) Síntesis de omecamtiv mecarbil.
CO2018013831A2 (es) Procesos para preparar oligómeros de morfolino fosforodiamidato
UY36110A (es) Inhibidores de quinasa relacionados con tropomiosina
CO2021007172A2 (es) Sales cristalinas de un inhibidor de calicreína plasmática
JOP20190163B1 (ar) منشط nrf2
CL2023000605A1 (es) Desimetrización de diol mediante sustitución aromática nucleófila
BR112018074330A2 (pt) processos para preparar oligômeros morfolino fosforodiamidato
CO2022000748A2 (es) Compuesto de pirazolopirimidina, método de preparación para el mismo y sus aplicaciones
MX2019011517A (es) Proceso para producir analogos de anillo de arilomicina.
MX2021012286A (es) Nuevas opciones sinteticas hacia la manufactura de (6r,10s)-10-{4-[5-cloro-2-(4-cloro-1h-1,2,3-triazol-1-il)fenil]-6 -oxo-1(6h)-pirimidinil}-1-(difluorometil)-6-metil-1,4,7,8,9,10-he xahidro-11,15-(meteno)pirazol[4,3-b][1,7]diazaciclotetradecin-5(6 h)-ona.
JP1722524S (ja) 美顔器用アタッチメント
CL2021000663A1 (es) Proceso para la producción de gas de síntesis.
CY1123076T1 (el) Ενωσεις βενζο-ν-υδροξυ αμιδιου που εχουν αντικαρκινικη δραστikothta
AR121730A1 (es) Nuevo promotor y procedimiento para producir glutatión usando el mismo
CL2019000294A1 (es) Síntesis de (s)-2-amino-4-metil-1-((r)-2-metiloxirano-2-il)-pentan-1-ona y sales farmacéuticamente aceptables de la misma.